NZ534231A - Use of acylaminoalkenylene-amide derivatives in treatment of functional motility disorders of the viscera - Google Patents
Use of acylaminoalkenylene-amide derivatives in treatment of functional motility disorders of the visceraInfo
- Publication number
- NZ534231A NZ534231A NZ534231A NZ53423103A NZ534231A NZ 534231 A NZ534231 A NZ 534231A NZ 534231 A NZ534231 A NZ 534231A NZ 53423103 A NZ53423103 A NZ 53423103A NZ 534231 A NZ534231 A NZ 534231A
- Authority
- NZ
- New Zealand
- Prior art keywords
- phenyl
- hydrogen
- methyl
- formula
- indol
- Prior art date
Links
- 230000004899 motility Effects 0.000 title claims abstract description 9
- 210000001835 viscera Anatomy 0.000 title claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 208000035475 disorder Diseases 0.000 claims abstract description 11
- 230000009278 visceral effect Effects 0.000 claims abstract description 10
- 230000004044 response Effects 0.000 claims abstract description 8
- 208000002551 irritable bowel syndrome Diseases 0.000 claims abstract description 7
- 201000006549 dyspepsia Diseases 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 208000018522 Gastrointestinal disease Diseases 0.000 claims abstract description 3
- 208000014540 Functional gastrointestinal disease Diseases 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 31
- 239000001257 hydrogen Substances 0.000 claims description 31
- -1 3,5-bistrifluoromethyl-phenyl Chemical group 0.000 claims description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
- 150000002431 hydrogen Chemical group 0.000 claims description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 230000028327 secretion Effects 0.000 claims description 7
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 6
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 230000008602 contraction Effects 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- 125000004361 3,4,5-trifluorophenyl group Chemical group [H]C1=C(F)C(F)=C(F)C([H])=C1* 0.000 claims description 2
- 125000005059 halophenyl group Chemical group 0.000 claims description 2
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 claims 6
- 102100024304 Protachykinin-1 Human genes 0.000 claims 6
- 101800003906 Substance P Proteins 0.000 claims 6
- 230000002572 peristaltic effect Effects 0.000 claims 5
- 230000008855 peristalsis Effects 0.000 claims 3
- 241000700199 Cavia porcellus Species 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 2
- 230000001186 cumulative effect Effects 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 244000068485 Convallaria majalis Species 0.000 claims 1
- 235000009046 Convallaria majalis Nutrition 0.000 claims 1
- 235000000836 Epigaea repens Nutrition 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000000763 evoking effect Effects 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 210000003405 ileum Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 210000004876 tela submucosa Anatomy 0.000 claims 1
- 230000001960 triggered effect Effects 0.000 claims 1
- 239000001373 (E)-2-methylpent-2-enoic acid Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 206010020751 Hypersensitivity Diseases 0.000 description 8
- 208000026935 allergic disease Diseases 0.000 description 8
- 230000009610 hypersensitivity Effects 0.000 description 8
- NGFQXYLWQODUIL-UHFFFAOYSA-N cyclohexylazanide Chemical compound [NH-]C1CCCCC1 NGFQXYLWQODUIL-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 230000000112 colonic effect Effects 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- CZRKBWYUKKBUMS-OAHLLOKOSA-N (4S)-4-[[3,5-bis(trifluoromethyl)benzoyl]-methylamino]-5-(3,4-dichlorophenyl)pent-2-enoic acid Chemical compound C([C@H](N(C)C(=O)C=1C=C(C=C(C=1)C(F)(F)F)C(F)(F)F)C=CC(O)=O)C1=CC=C(Cl)C(Cl)=C1 CZRKBWYUKKBUMS-OAHLLOKOSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 125000004188 dichlorophenyl group Chemical group 0.000 description 2
- 125000004212 difluorophenyl group Chemical group 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- CZRKBWYUKKBUMS-HNNXBMFYSA-N (4r)-4-[[3,5-bis(trifluoromethyl)benzoyl]-methylamino]-5-(3,4-dichlorophenyl)pent-2-enoic acid Chemical compound C([C@@H](N(C)C(=O)C=1C=C(C=C(C=1)C(F)(F)F)C(F)(F)F)C=CC(O)=O)C1=CC=C(Cl)C(Cl)=C1 CZRKBWYUKKBUMS-HNNXBMFYSA-N 0.000 description 1
- YNSHGWWUZRMHMJ-OAHLLOKOSA-N (4s)-4-[[3,5-bis(trifluoromethyl)benzoyl]-methylamino]-5-(3,4-dibromophenyl)pent-2-enoic acid Chemical compound C([C@H](N(C)C(=O)C=1C=C(C=C(C=1)C(F)(F)F)C(F)(F)F)C=CC(O)=O)C1=CC=C(Br)C(Br)=C1 YNSHGWWUZRMHMJ-OAHLLOKOSA-N 0.000 description 1
- 125000006512 3,4-dichlorobenzyl group Chemical group [H]C1=C(Cl)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 description 1
- 125000006509 3,4-difluorobenzyl group Chemical group [H]C1=C(F)C(F)=C([H])C(=C1[H])C([H])([H])* 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010005052 Bladder irritation Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- BOWUOGIPSRVRSJ-YFKPBYRVSA-N L-2-aminohexano-6-lactam Chemical group N[C@H]1CCCCNC1=O BOWUOGIPSRVRSJ-YFKPBYRVSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 210000004953 colonic tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000036378 peristaltic reflex Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000004360 trifluorophenyl group Chemical group 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0203061.7A GB0203061D0 (en) | 2002-02-08 | 2002-02-08 | Organic compounds |
| PCT/EP2003/001227 WO2003066062A1 (en) | 2002-02-08 | 2003-02-07 | Use of acylaminoalkenylene-amide derivatives in functional motility disorders of the viscera |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ534231A true NZ534231A (en) | 2007-02-23 |
Family
ID=9930743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ534231A NZ534231A (en) | 2002-02-08 | 2003-02-07 | Use of acylaminoalkenylene-amide derivatives in treatment of functional motility disorders of the viscera |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20050203164A1 (https=) |
| EP (2) | EP1476167A1 (https=) |
| JP (2) | JP2005516994A (https=) |
| KR (2) | KR20100100994A (https=) |
| CN (1) | CN1301714C (https=) |
| AU (1) | AU2003244446B2 (https=) |
| BR (1) | BR0307479A (https=) |
| CA (1) | CA2471964A1 (https=) |
| GB (1) | GB0203061D0 (https=) |
| IL (2) | IL162816A0 (https=) |
| MX (1) | MXPA04007640A (https=) |
| NO (1) | NO20043735L (https=) |
| NZ (1) | NZ534231A (https=) |
| PL (1) | PL370255A1 (https=) |
| RU (1) | RU2353356C2 (https=) |
| TW (1) | TWI330177B (https=) |
| WO (1) | WO2003066062A1 (https=) |
| ZA (1) | ZA200404960B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0203061D0 (en) * | 2002-02-08 | 2002-03-27 | Novartis Ag | Organic compounds |
| EP1686985A2 (en) | 2003-10-27 | 2006-08-09 | Novartis AG | Use of neurokinin antagonists in the treatment of urinary incontinence |
| CN101568331A (zh) | 2006-09-08 | 2009-10-28 | 奥尔制药有限公司 | 减少或缓解消化道炎症的方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5217996A (en) * | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
| US5457101A (en) * | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
| MX9706394A (es) * | 1995-02-22 | 1997-11-29 | Novartis Ag | Compuestos de 1-aril-2-acilamino-etano y su uso como antagonistas de neuroquinina, especialmente neuroquinina-1. |
| CR5278A (es) * | 1995-03-24 | 1996-07-04 | Lilly Co Eli | Formulacion oral de 2-metil-tieno-benzodiacepina |
| GB9525296D0 (en) * | 1995-12-11 | 1996-02-07 | Merck Sharp & Dohme | Therapeutic agents |
| MY132550A (en) * | 1996-08-22 | 2007-10-31 | Novartis Ag | Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists |
| GB9708484D0 (en) * | 1997-04-25 | 1997-06-18 | Merck Sharp & Dohme | Therapeutic agents |
| PL191496B1 (pl) * | 1997-07-02 | 2006-05-31 | Merck & Co Inc | Odmiana polimorficzna 2-(R)-{1-(R) -[3,5-bis(trifluorometylo)-fenylo]etoksy} -3-(S)-(4-fluoro) fenylo-4-[3-(5-okso-1H,4H-1,2,4-triazolo)metylo] morfoliny, sposób jej wytwarzania, zawierająca ją kompozycja farmaceutyczna i jej zastosowanie |
| TW520370B (en) * | 1998-11-20 | 2003-02-11 | Meiji Seika Kaisha | Benzooxazole derivatives and a pharmaceutical composition containing the derivatives as an active ingredient |
| RU2161894C1 (ru) * | 1999-08-10 | 2001-01-20 | НИФ "Ультрасан" | Лечебно-профилактическая композиция |
| GB0010958D0 (en) | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
| US20040058914A1 (en) * | 2000-12-22 | 2004-03-25 | Takayuki Doi | Combination drugs |
| GB0203061D0 (en) * | 2002-02-08 | 2002-03-27 | Novartis Ag | Organic compounds |
-
2002
- 2002-02-08 GB GBGB0203061.7A patent/GB0203061D0/en not_active Ceased
-
2003
- 2003-02-07 AU AU2003244446A patent/AU2003244446B2/en not_active Ceased
- 2003-02-07 IL IL16281603A patent/IL162816A0/xx unknown
- 2003-02-07 BR BR0307479-0A patent/BR0307479A/pt not_active IP Right Cessation
- 2003-02-07 NZ NZ534231A patent/NZ534231A/en not_active IP Right Cessation
- 2003-02-07 US US10/501,496 patent/US20050203164A1/en not_active Abandoned
- 2003-02-07 TW TW092102519A patent/TWI330177B/zh not_active IP Right Cessation
- 2003-02-07 PL PL03370255A patent/PL370255A1/xx not_active Application Discontinuation
- 2003-02-07 KR KR1020107017008A patent/KR20100100994A/ko not_active Ceased
- 2003-02-07 RU RU2004127132/15A patent/RU2353356C2/ru not_active IP Right Cessation
- 2003-02-07 EP EP03737323A patent/EP1476167A1/en not_active Ceased
- 2003-02-07 CA CA002471964A patent/CA2471964A1/en not_active Abandoned
- 2003-02-07 EP EP10163570A patent/EP2216025A3/en not_active Withdrawn
- 2003-02-07 KR KR10-2004-7012191A patent/KR20040081492A/ko not_active Ceased
- 2003-02-07 JP JP2003565486A patent/JP2005516994A/ja not_active Ceased
- 2003-02-07 WO PCT/EP2003/001227 patent/WO2003066062A1/en not_active Ceased
- 2003-02-07 CN CNB038034859A patent/CN1301714C/zh not_active Expired - Fee Related
- 2003-02-07 MX MXPA04007640A patent/MXPA04007640A/es active IP Right Grant
-
2004
- 2004-06-23 ZA ZA200404960A patent/ZA200404960B/en unknown
- 2004-07-01 IL IL162816A patent/IL162816A/en not_active IP Right Cessation
- 2004-09-07 NO NO20043735A patent/NO20043735L/no not_active Application Discontinuation
-
2007
- 2007-08-23 US US11/895,226 patent/US20070293473A1/en not_active Abandoned
-
2010
- 2010-07-22 JP JP2010164587A patent/JP2010241835A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040081492A (ko) | 2004-09-21 |
| US20070293473A1 (en) | 2007-12-20 |
| GB0203061D0 (en) | 2002-03-27 |
| EP2216025A3 (en) | 2010-11-10 |
| JP2005516994A (ja) | 2005-06-09 |
| EP2216025A2 (en) | 2010-08-11 |
| KR20100100994A (ko) | 2010-09-15 |
| ZA200404960B (en) | 2006-05-31 |
| TWI330177B (en) | 2010-09-11 |
| NO20043735L (no) | 2004-09-07 |
| PL370255A1 (en) | 2005-05-16 |
| EP1476167A1 (en) | 2004-11-17 |
| MXPA04007640A (es) | 2004-11-10 |
| JP2010241835A (ja) | 2010-10-28 |
| IL162816A (en) | 2010-11-30 |
| RU2004127132A (ru) | 2005-06-10 |
| US20050203164A1 (en) | 2005-09-15 |
| RU2353356C2 (ru) | 2009-04-27 |
| WO2003066062A1 (en) | 2003-08-14 |
| AU2003244446A1 (en) | 2003-09-02 |
| TW200302818A (en) | 2003-08-16 |
| AU2003244446B2 (en) | 2006-08-10 |
| CA2471964A1 (en) | 2003-08-14 |
| CN1301714C (zh) | 2007-02-28 |
| HK1077749A1 (en) | 2006-02-24 |
| BR0307479A (pt) | 2004-12-07 |
| IL162816A0 (en) | 2005-11-20 |
| CN1627947A (zh) | 2005-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3630101B1 (en) | Tegavivint for use in the treatment of pulmonary fibrosis | |
| SK25799A3 (en) | Heterocyclic metalloprotease inhibitors | |
| JP2002537332A (ja) | 内臓痛を予防及び治療するためのガバペンチン誘導体 | |
| EP1415667B1 (en) | Pancreatic juice secretion regulators comprising lpa receptor controller | |
| US20070293473A1 (en) | Use of acylaminoalkenylene-amide derivatives in functional motility disorders of the viscera | |
| JPH11505243A (ja) | Ａｉｉ受容体アンタゴニストの新規な薬理学的使用 | |
| FR2896157A1 (fr) | Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline. | |
| RS60154B1 (sr) | Soli kratkodelujućeg fenilalkilamina, blokatora kalcijumskih kanala, koje su visoko rastvorljive u vodi i njihova primena | |
| HK1145139A (en) | Use of acylaminoalkenylene-amide derivatives in irritable bowel syndrome and functional dyspepsia | |
| IE922378A1 (en) | Antihypertensive combination | |
| RU2700595C1 (ru) | Производное 3,6,9-триазатрициклотетрадекана и его применение для лечения депрессии | |
| JPH11246437A (ja) | 消化管粘膜保護剤 | |
| JPH06234630A (ja) | 中性メタロエンドペプチダーゼ阻害剤 | |
| AU2004283038B2 (en) | Use of neurokinin antagonists in the treatment of urinary incontinence | |
| HK1077749B (en) | Use of acylaminoalkenylene-amide derivatives in functional motility disorders of the viscera | |
| JP6875747B2 (ja) | 生薬成分を含む肺高血圧症の予防又は治療剤 | |
| SU1375129A3 (ru) | Способ получени новых тиокетеновых производных или их фармацевтически приемлемых солей | |
| WO2004037266A1 (en) | Compounds for the treatment of cough | |
| WO2004063201A1 (ja) | 統合失調症治療剤 | |
| JPH11286454A (ja) | 虚血性脳血管障害の治療剤 | |
| JPS6013714A (ja) | 胃腸細胞保護剤 | |
| JP2006503870A (ja) | 睡眠障害の処置のための５−ｈｔ２受容体拮抗薬の使用 | |
| MX2008008894A (en) | Combination of triazine derivatives and insulin secretion stimulators | |
| JPH0867632A (ja) | 中性メタロエンドペプチダーゼ阻害剤 | |
| HK1128232A (en) | Combination of triazine derivatives and insulin sensitisers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| LAPS | Patent lapsed |